Boehringer Ingelheim BioXcellence
German pharma Boehringer invests decades in disease targets - K-selected drug development accepting low offspring count for high success probability per program.
German pharma Boehringer invests decades in disease targets - K-selected drug development accepting low offspring count for high success probability per program.